Status:
RECRUITING
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Solid Tumours
Eligibility:
All Genders
18+ years
Brief Summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R ...
Eligibility Criteria
Inclusion
- Participant is an adult (according to the age of majority as defined by local regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Exclusion
- Participant has a prior or current diagnosis of haematological malignancy
Key Trial Info
Start Date :
August 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT04529122
Start Date
August 27 2020
End Date
December 31 2026
Last Update
December 18 2025
Active Locations (136)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Alexander Fleming
Buenos Aires, Argentina, 1426
2
CEMIC
Buenos Aires, Argentina, C1431FWN
3
Lkh-Univ. Klinikum Graz
Graz, Austria, 8036
4
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil, 90035-001